Flamel Technologies S.A. (ADR)  

(Public, NASDAQ:FLML)   Watch this stock  
Find more results for flml
9.05
-0.16 (-1.74%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.90 - 9.39
52 week 8.67 - 26.09
Open 9.16
Vol / Avg. 270,566.00/374,529.00
Mkt cap 358.72M
P/E     -
Div/yield     -
EPS -1.70
Shares 40.50M
Beta 1.34
Inst. own 81%
Mar 17, 2016
Full Year 2015 Flamel Technologies SA Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 13, 2016
Flamel Technologies SA at ROTH Conference Add to calendar
Feb 23, 2016
Flamel Technologies SA at RBC Capital Markets Healthcare Conference - 9:30AM EST - Add to calendar
Feb 8, 2016
Flamel Technologies SA Acquires FSC Pediatrics M&A Call
Nov 18, 2015
Flamel Technologies SA at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -62.73% -601.85%
Operating margin -30.60% -635.24%
EBITD margin - -141.48%
Return on average assets - -61.23%
Return on average equity - -1156.13%
Employees 109 -
CDP Score - -

Address

33, avenue du Dr. Georges Levy, Venissieux Cedex, PARC CLUB DU MOULIN A VENT
VENISSIEUX, 69693
France
+33-4-72783434 (Phone)
+33-4-72783435 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Flamel Technologies SA is a pharmaceutical company. The Company’s focus is on the development of safer and more efficacious formulations and other medical needs in the process. Micropump platform applied to sodium oxybate in a First-in-Man (FIM) clinical study in healthy volunteers. The Company’s products include Bloxiverz and Coreg CR. Bloxiverz (Neostigmine Methylsulfate Injection) is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Coreg CR, the lead product using the Company’s Micropump drug delivery platform. Coreg CR is an extended-release formulation of Coreg (carvedilol phosphate), a non-selective antagonist of Beta 1, Beta 2 adrenergic receptors and a selective antagonist of Alpha 1 adrenergic receptors.

Officers and directors

Stephen H. Willard Non-Executive Chairman of the Board
Bio & Compensation  - Reuters
Michael S. Anderson Chief Executive Officer, Director
Bio & Compensation  - Reuters
Michael F. Kanan Chief Financial Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Rafael Jorda Chief Operating Officer, Executive Vice President
Bio & Compensation  - Reuters
Sandra Hatten Senior Vice President - Quality and Regulatory Affairs
Bio & Compensation  - Reuters
Steven A. Lisi Senior Vice President - Business and Corporate Development
Bio & Compensation  - Reuters
Gregory J. Davis Vice President - Business and Corporate Development
Bio & Compensation  - Reuters
Gregg Stetsko Ph.D. Vice President - Research & Development
Age: 56
Bio & Compensation  - Reuters
Catherine Castan Director - Micropump Platform (Oral Drugs) and Intellectual Property
Bio & Compensation  - Reuters
Christian Kalita Pharmacist and Director - Quality Assurance and Regulatory Affairs
Bio & Compensation  - Reuters